Company intelligence / Profile preview
ProKidney
Winston-Salem, North Carolina, United Statesprokidney.com ↗
- Ownership
- Public · PROK
- Employees
- ~330
- Development stage
- Phase 3
01
Overview
ProKidney is conducting Phase 3 trials for rilparencel (REACT), which has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. The company recently decided to discontinue one of its Phase 3 trials (PROACT 2) while focusing on the U.S.-based PROACT 1 trial, which is expected to deliver topline results by Q3 2027. Previous trials indicate that rilparencel is well tolerated by patients with moderate-to-severe CKD.
- Therapeutic areas
- Nephrology
- Modalities
- Cell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Financials
- Market cap
- $358.1M
- Total revenue
- $893K
- Enterprise value
- $180.1M
Beyond the preview
Go deeper on ProKidney.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProKidney.